As such, through in vitro analyses, we sought evidence that supported the pharmacological redirection of PARP inhibitors, focusing on PARP1 due to its prominent role in DNA repair signaling [10] for the treatment of ALL BCR::ABL1 p190+ models through the exploration of synthetic lethality pathways. Here, ABL1 is linked to acute lymphoblastic leukemia.